Celgene down 13% after it pulls Revlimid filing
6/21/12 8:08 AM ET (MarketWatch)
NEW YORK (MarketWatch) -- Celgene Corp. fell 12.6% in premarket trades Thursday after the drug firm said it's withdrawing its new indication submission to European regulators for its Revlimid medicine for multiple myeloma, a cancer that affects a type of white blood cells. Celgene said it plans to resubmit its application with more mature data. In the U.S., Celgene said it's re-evaluating its Revlimid newly diagnosed submission to the U.S. Food and Drug Administration and expects to submit an application in 2013. It's proceeding with submissions for Revlimid in Switzerland, Australia and other core markets.